Press Release Details

The four posters were released for the 2020 American College of Medical Genetics and Genomics’ (ACMG) Annual Clinical Genetics Meeting.

SAN DIEGO, May 27, 2020— Progenity, a biotechnology company with an established track record of success in developing and commercializing molecular testing products, has released four posters for the 2020 American College of Medical Genetics and Genomics’ (ACMG) Annual Clinical Genetics Meeting, which has transitioned to a Digital Edition platform in order to ensure the health and safety of registered attendees. Progenity has shared critical analysis of specialized carrier screening tests and communication tools to support the mission of providing actionable results that enable patients to make informed medical decisions.

• Title: Suspected maternal vs. fetal sex chromosome cell-free DNA screening results impact diagnostic testing uptake and follow-up, Abstract Number: 753
• Title: Assessing the positivity rate of carriers of lysosomal storage disorders with treatment benefits, Abstract Number: 658
• Title: Chatbot successfully assesses risk for hereditary cancer in obstetrics and gynecology practices across the United States, Abstract Number: 122
• Title: Consent forms marketed by commercial laboratories vary in readability, Abstract Number: 818

The abstracts and the full posters are available through the 2020 ACMG Annual Clinical Genetics Meeting Digital Edition site, or visit our clinical publications page.

About Progenity

Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For more information on how Progenity is helping clinicians and patients prepare for life, please visit www.progenity.com.

Progenity Media Contact

Kate Blom-Lowery
CG Life
kblomlowery@cglife.com
(858) 457-2436